"The consumer healthcare market has experienced a steady stream of mergers and acquisitions in recent years. Some of this has created small ripples — like pebbles being gently tossed into still waters. Then there are the mega-mergers that have had a Tsunami-like affect," writes Dave Wendland, Hamacher Resource Group VP, in his latest blog entry.
Rob Hooper, national sales manager for OTC with Actavis Pharmaceutical, sat down with DSN to discuss how Actavis is preparing for the inaugural NACDS Total Store Expo. Actavis Pharmaceutical, one of the leaders in the OTC private label industry and recently acquired by Watson Pharmaceutical, plans to leverage its extensive experience within the prescription medicine business to offer best-in-class options across store brand products.
The year 2012 is coming to an end, and it's been a big year for generic drugs. It's the year that the most lucrative drug of all time became commoditized. It's the year that Watson bought Actavis for $5.6 billion. And it's the year the FDA released draft guidance for biosimilars regulations. All of these events speak to some of the most important trends in the world of generics — trends that are often interrelated.
Sanofi on Monday acquired the rights to Afrezza Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with Type 1 and Type 2 diabetes, from MannKind in a deal that could be worth as much as $925 million.
Capsa Solutions, a provider of medication management systems, mobile computing carts and medical cart platforms for healthcare facilities, announced the acquisition of Kirby Lester, LLC — a provider of automated medication dispensing solutions in retail, institutional, hospital and ambulatory pharmacy settings.
While sales of heat and ice packs are relatively flat — the category generated slight growth of 0.2% to $235.9 million for the 52 weeks ended April 20 across total U.S. multi-outlets, according to IRI — there has been some positive momentum within the category.
Roche on Wednesday announced that Genentech, a member of the Roche Group, has entered into a definitive agreement to acquire Seragon Pharmaceuticals, a privately held biotechnology company based in San Diego.
Kroger and Vitacost.com on Wednesday announced a definitive merger agreement under which Kroger will purchase all outstanding shares of Vitacost.com for $8 per share in cash, or approximately $280 million.
Performance Health, the manufacturer and marketer behind TheraBand, Biofreeze, Perform, Cramer, Bon Vital' and Hygenic products, last week announced that it acquired TheraPearl, the creator of hot and cold therapy products.
In preparation for the grand re-opening of the Rite Aid located at 300 North Canon Dr. in Beverly Hills, the company on Thursday announced it will kick off the celebration by hosting 21 days of special events for customers.
Teva Pharmaceutical and Labrys Biologics, a privately-held development stage biotechnology company focused on treatments for chronic migraine and episodic migraine, on Tuesday announced that Teva has entered into a definitive agreement to acquire Labrys in a deal for $200 million in upfront payment in cash at closing as well as up to $625 million in contingent payments upon achievement of certain pre-launch milestones.
Gov. Alejandro García Padilla on Wednesday announced an agreement by Puerto Rico Industrial Development Co. with Actavis that will allow the pharmaceutical manufacturer to develop a solid dosage manufacturing and packing facility in its Manati site and expand its current hormone production in Fajardo.